委常委、宣传部 部长罗丽思出席 活动并颁奖。 经评委组公平公 正评审，大赛共 评选出金奖2 名、银奖3名、 铜奖5名、优秀 奖10名、优秀组 织奖3名。 兴宁市"齐昌 杯"杯花舞大赛 金奖出炉，20镇 街共展非遗风采 _南方+_南方 plus 2月19日下午， 2026年兴宁 市"齐昌杯"杯花 舞大赛在明珠文 化广场精彩上 演。本次大赛 以"千灯璀璨 杯 花竞韵"为主 题，是兴宁市 2026年"上灯 +"系列活动的重 要内容。兴宁市 颁奖仪式。 本次大赛由兴宁 市委宣传部指 导，兴宁市文广 旅体局、市文明 办、市文联、市 融媒体中心联合 主办，兴宁市文 化馆、梅州瓷语 艺术工作室承 办。来自全市各 镇（街）的20支 参赛队伍同台竞 技、尽展风采， 以省级非物质文 化遗产兴宁杯花 舞为载体，生动 传承客家优秀传 统文化，丰富春 节期间群众精神 文化生活，助力 兴宁市"一立四 强"建设和文旅 融合高质量发 展。 获奖名单如下： 金奖（2名） 罗浮镇、石马镇 银奖（3名） 刁坊镇、福兴街 道、黄槐镇 铜奖（5名） 兴田街道、大坪 镇、新陂镇、罗 岗镇、坭陂镇 优秀奖（10名） 宁新街道、径南 镇、龙田镇、叶 塘镇、 ...

文化年礼送到家 门口，汕头仙门 城"村晚"潮味十 足_南方+_南方 plus 2月19日（正月 初三）晚，汕头 市潮南区仙城镇 仙门城社区南门 广场张灯结彩、 欢歌笑语，一 场"潮"味十足 的"'粤美村晚'迎 新春"文艺志愿 服务活动在此火 热开演。来自 省、市、区的艺 术家与基层群众 齐聚一堂，用乡 音乡韵共贺新 春，为乡亲们送 上了一份热气腾 腾、情意浓浓的 文化年礼。 本次活动以"潮 韵贺新春 ·和美 仙门城"为主 全体演职人员合影留念，共贺"粤美村晚"圆满成功。 题，紧扣广东省 文艺志愿服 务"百千万工 程"，旨在通过 文化艺术结对帮 扶，丰富基层文 化生活，展现广 东"和美乡村"的 新颜与活力。 当晚，由乐尔弦 乐团带来的弦乐 重奏《春晓》 《赛马》为整场 活动拉开序幕， 悠扬的乐声瞬间 点燃了现场浓浓 的节日气氛。随 后,市曲艺家协 会相继带来《生 活杂谈》《家的 味道》的相声、 小品精彩表演， 同时，市文艺志 愿者协会带来的 《依然爱你》 《荔枝红了》 《燃动青春》舞 蹈表演与市舞蹈 家协会的《澜水 见月圆》独舞， 犹如流动的文化 画卷,生动诠释 本土文化的深厚 底蕴。 市曲艺家协会与 市戏剧家 ...

2026年新春期 间，"粤美村 晚"迎新春系列 活动在南粤大地 遍地开花，这股 源自乡野的文化 热潮，以其广泛 的覆盖范围与深 厚的群众基础， 为理解文化如何 融入基层治理、 赋能乡村振兴， 提供了一个生动 的观察窗口。当 城镇化进程深刻 改变乡村社会结 构时，"粤美村 晚"何以激发如 此广泛而自觉的 "粤美村晚"何 以"出圈"_南方 +_南方plus 用。1949年后， 国家力量介入乡 村文化建设，通 过设立文化站、 组织文艺汇演、 送戏下乡等方 式，建立起覆盖 乡村的公共文化 服务体系。这一 模式在保障基本 文化供给的同 时，也形成 了"自上而下输 送、村民被动接 收"的基本格 局。 社会参与？它所 折射的，是乡村 公共文化生活怎 样的深层变化？ 对于当下乡村治 理的转型与乡村 振兴的推进，又 能带来哪些启 示？本文尝试 将"粤美村晚"置 于乡村公共文化 生活的演进脉络 中，从文化动 员、基层治理与 乡村振兴三重维 度，解析其内在 逻辑，并探讨这 一富具传统与现 代的文化实践对 乡村建设的长远 意义。 一、乡村公共文 化空间的当代重 构 2月6日，河源凤安镇，"粤美村晚"舞台下座无虚席，人们全家出动前来共 ...

大年初五凤村为 你添喜气！粤美 村晚 "艺" 起闹 新春_南方+_南 方plus 粤美村晚贺新春 备受期待的"村 艺盎然 和美凤 村" 2026德庆县凤村 镇粤美村晚迎新 春文艺汇演 即将于大年初五 （2月21日）热 闹启幕！ 凤村镇粤美村晚 迎新春文艺汇演 活动时间：2026 年2月21日 20:00 活动地点：德庆 县凤村镇人民政 府 活动亮点抢先看 全民共演共乐 这场村晚承载着 凤村的乡土情怀 与发展期盼， 诚邀八方乡邻欢 聚一堂，共赏乡 韵文艺，同庆新 春佳节！ 活动主题："村 艺盎然 和美凤 村"2026德庆县 主角是乡亲：节 目由凤村镇中心 幼儿园、中心小 学、凤村中学、 雏 凤 童 声 合 唱 团、飞凤舞蹈队 等本土团队自编 自 演 ， 真 正 实 现"百姓演、百 姓 看 、 百 姓 乐" 。 乡音乡情浓：快 板《绿美凤村展 新颜》直接唱响 凤村发展新貌， 合唱《童谣在我 心 》 《 风 起 凤 鸣》等节目，用 乡音传递对家乡 的热爱。 传统与新潮碰撞 传统韵味足：粤 剧《柳毅传书》 选段、粤曲《彩 云追月》、二胡 独奏《赛马》、 舞龙表演《龙腾 飞跃》等，展现 岭南戏曲、民乐 和民俗魅力。 现 ...

Core Insights - Fennec Pharmaceuticals has presented new real-world data supporting the use of PEDMARK (sodium thiosulfate injection) in adults with head and neck cancers, indicating its safe administration at least six hours after cisplatin treatment without compromising the drug's antitumor efficacy [1][2][5] - The findings highlight the potential of PEDMARK to mitigate cisplatin-induced hearing loss, a significant survivorship issue, with most high-risk patients showing no measurable hearing loss during or after treatment [1][4][5] Company Overview - Fennec Pharmaceuticals is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients, having received FDA approval in September 2022 and subsequent approvals in Europe and the UK [22][24] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the UK, Australia, and New Zealand [23] Industry Context - Cisplatin is widely used in treating solid tumors but is associated with a high incidence of hearing loss, affecting 60-90% of patients depending on treatment parameters [7][8] - The introduction of PEDMARK represents a significant advancement in addressing the long-term quality of life issues faced by cancer survivors due to treatment-induced hearing loss [12][9]

Core Insights - BioStem Technologies, Inc. will present at the 46th Annual TD Cowen Healthcare Conference in Boston, MA, highlighting its focus on perinatal tissue-derived products for advanced wound care [1]. Company Overview - BioStem Technologies is a leading innovator in the MedTech sector, specializing in the development, manufacturing, and commercialization of allografts for regenerative therapies derived from perinatal tissue [3]. - The company utilizes its proprietary BioRetain® processing method, which is designed to maintain growth factors and preserve tissue structure, leveraging the latest research in regenerative medicine [3]. - BioStem's quality management system and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP) [3]. - The company's product portfolio includes brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and Neox® and Clarix® product lines [3].

这个春节假期，全球资本市场上演了一出"你方唱罢我登场"的热闹大戏，而休市中的A股，似乎成了这场盛宴中最受期待的"压轴嘉宾"。 | く 気 | 亚太指数 () | | | | --- | --- | --- | --- | | 名称 | 最新 | 涨幅 | 流 | | 恒生指数 | 26705.94 0.52% | | 133.8 | | HSI | | | | | 恒生科技指数 5367.52 0.13% | | | 7.1 | | HSTECH | | | | | 国企指数 | 9070.32 0.42% | | 37.5 | | HSCEI | | | | | AH 投稿价 | 116.21 -1.03% | | -1.2 | | HSAHP | | | | | 台湾加权 | 33605.71 | 1.61% | 5377 | | TWII | | | | | 日经 225 | 57467.83 | 0.57% | 323.9 | | N225 | | | | | 富时新加坡海峡时报 4996.70 | | 1.18% | 58.1 | | STI 延 | | | | | ETE KOSPI | 5677 ...

Core Viewpoint - The silver market experienced extreme volatility in 2025 and early 2026, driven by liquidity influx, strong industrial demand, and self-reinforcing market sentiment, leading to a dramatic price surge followed by a sharp decline [1][3][5][8]. Group 1: Liquidity and Market Dynamics - In 2025, the Federal Reserve's interest rate cuts led to a surge in liquidity, attracting significant capital into the silver market, which has a total market value only one-tenth that of gold [3]. - The influx of retail and speculative investors, drawn by low prices, resulted in unprecedented premiums for silver funds and record-high open interest in COMEX silver futures [3]. - The market's structure became increasingly crowded with long positions, setting the stage for a sharp correction when prices began to fall [9]. Group 2: Industrial Demand - Silver transitioned from being a mere precious metal to a critical industrial component, particularly in the photovoltaic sector, which consumed about one-sixth of the global silver production in 2025 [4]. - The demand for silver surged due to advancements in high-efficiency battery technologies and the expansion of data centers and electric vehicles, while supply remained rigid due to the nature of silver extraction [4]. - The London Bullion Market Association reported that deliverable silver stocks fell to levels sufficient for only 1.2 months of global consumption, indicating a precarious supply situation [4]. Group 3: Market Sentiment and Price Fluctuations - By the end of 2025, social media buzz around silver investments created a speculative bubble, with prices soaring over 140% throughout the year [5]. - On January 29, 2026, silver prices peaked at $121.65 per ounce before a sudden collapse triggered by the nomination of a hawkish Federal Reserve chair, which reversed market expectations for further rate cuts [8]. - The market's fragile structure led to a cascade of forced liquidations, resulting in a record single-day price drop of over 35%, with prices plummeting to near $74 [9]. Group 4: Long-term Supply and Demand Outlook - Despite the short-term volatility, the World Silver Survey projected a supply deficit of 67 million ounces in 2026, indicating persistent structural demand from industries like photovoltaics and AI [11]. - The rising silver prices have pressured manufacturers, particularly in the photovoltaic sector, to innovate and reduce silver usage, potentially impacting long-term demand growth [15]. - Silver's dual role as both an industrial metal and a financial asset creates a complex market dynamic, with its price sensitivity to monetary policy and industrial demand [12][15].

Core Viewpoint - Ranger Energy Services, Inc. will report its fourth quarter and full year 2025 financial and operating results on March 5, 2026, before the market opens [1] Financial Reporting - The earnings conference call will take place at 10:00 a.m. Eastern time (9:00 a.m. Central time) following the financial results announcement [1] - Interested parties can join the call by dialing 1-833-255-2829 for domestic calls or 1-412-902-6710 for international calls [1]

The anticipated EPS of -$0.70 and revenue of $193.3 million for the quarter ending December 2025.Negative P/E ratio of -40.57 but potential growth indicated by revenue projections.Concerns over negative operating cash flow with an enterprise value to operating cash flow ratio of -91.91.Axsome Therapeutics, listed on NASDAQ:AXSM, is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is set to release its quarterly earnings on February 23, 2026. Wall ...